Tag: CBT > DEA Rescheduling: Page 11

Hemp Research

Risky Research

January 5, 2023

Cannabis Rescheduling

Helpful, or Yet Another Hurdle?

Many industry experts agree President Joe Biden’s three-step cannabis reform plan was historic and removing the plant from the list of Controlled Substances would be ideal. But a rescheduling could make things more complex—or even a 'disaster'—for state-legal markets.

December 23, 2022

2022 Election and Cannabis

Will Cannabis Policy Change?

Past reviews of cannabis’s Schedule I classification in the Controlled Substances Act—the most recent of which took five years and ended in 2016—have never moved the needle with the Drug Enforcement Agency. Many wonder if this time will be different with the directive coming from the president.

October 26, 2022

Legislation and Regulation

Biden's Order to Review Cannabis 'Truly Historic,' But What's at Stake?

Many industry experts agree removing cannabis from the list of Controlled Substances would be ideal. But a rescheduling could make things more complex—or even a 'disaster' for the state-legal industry.

October 26, 2022

Legislation and Regulation

Reschedule? Deschedule? A Conversation with Leah Heise Following President Biden’s Announcement

The president has requested a review of cannabis’s status under the Controlled Substances Act. What might happen next?

October 17, 2022

SAFE Banking Act

‘The Clash Between State and Federal Law in the Cannabis Industry’: 4 Key Takeaways on Federal Policy Reform Efforts

Cozen O’Connor attorneys share insight on where cannabis policy reform might be headed to address the disconnect between federal prohibition and state-legal programs.

June 24, 2022

Hemp

HIA Supports Delta-8 Production, But Calls for Market Regulation

"Prohibition is a failed concept," the HIA said in a statement in conjunction with a legal opinion drafted by Kight Law.

June 23, 2021

Finance

Virginia and Missouri Launch Medical Cannabis Sales, New York Governor Renews Adult-Use Legalization Push: Week in Review

This week marked the opening of new medical cannabis markets in Virginia and Missouri as the states’ first dispensaries opened their doors to patients.

October 24, 2020

Legislation and Regulation

Amicus Briefs Filed in Support of Dr. Sue Sisley’s Petition to Facilitate Medical Cannabis Research for Veterans with PTSD

Sisley is petitioning the Ninth Circuit to rule that the DEA’s five-part test to assess if a drug has medical use and can be rescheduled is arbitrary and capricious.

October 20, 2020

Legislation and Regulation

DEA Proposes New Hemp and CBD Regulations to Comply with 2018 Farm Bill

The DEA emphasizes the new rules are only to conform to the 2018 Farm Bill and have already taken effect.

August 21, 2020

Compliance

NCIA Calls for Cannabis Oversight Change

In comments to the DEA’s request for information, NCIA advises cannabis research be overseen by health agency.

May 13, 2020

Legislation and Regulation

Cannabis and COVID-19: How the Pandemic Will Influence the Future of the Cannabis Industry

COVID-19 has affected every person and every business in the U.S. in some small or tragically large way.

April 8, 2020